You are viewing the site in preview mode

Skip to main content

Advertisement

Table 6 Summary of phase 3 trials of ABT-450/r/ABT-267, ABT-333 plus ribavirin in hepatitis C virus genotype 1

From: Molecular diagnostics in the management of chronic hepatitis C: key considerations in the era of new antiviral therapies

Study Population Treatment/Duration SVR12
PEARL-II GT1b treatment-experienced (N = 179) 3-DAA + RBV, 12 weeks (n = 88) 97%(85/88)
   3-DAA only, 12 weeks (n = 91) 100% (91/91)
PEARL-III GT1b treatment-naive (N = 419) 3-DAA + RBV, 12 weeks (n = 210) 99% (209/210)
   3-DAA only, 12 weeks (n = 209) 99% (207/209)
PEARL-IV GT1a treatment-naive (N = 305) 3-DAA + RBV, 12 weeks (n = 100) 97% (97/100)
   3-DAA only, 12 weeks (n = 205) 90% (185/205)
TURQUOISE-II GT1 treatment-naive and treatment-experienced with compensated cirrhosis (N = 380) 3-DAA + RBV, 12 weeks (n = 208) 92% (191/208)
   3-DAA + RBV, 24 weeks (n = 172) 96% (165/172)
SAPPHIRE-I GT1 treatment-naive (N = 631) 3-DAA + RBV, 12 weeks (n = 473) 96% (455/473)
SAPPHIRE-II GT1 treatment-experienced (N = 394) 3-DAA + RBV, 12 weeks (n = 297) 96% (286/297)
  1. SVR: Sustained virologic response. GT: Genotype. DAA: Direct acting antivirals. RBV: ribavirin.